antigens. Its pipeline includes multiple autologous and controllable CAR-T therapy programs, such as a BCMA-targeted cell therapy in clinical development for patients with relapsed or refractory multiple myeloma and additional candidate programs addressing other hematologic targets. Arcellx collaborates with external partners to co-develop and prepare its product candidates for potential regulatory submissions and broader use by clinicians and patients.